OBJECTIVE: To compare the respective efficiency of CSF tau (quantitative) and CSF 14-3-3 protein (qualitative) in the diagnosis of prion disease. METHODS: We made measurements on 420 live subjects, who subsequently underwent a postmortem neuropathology examination, including protein chemistry, immunohistochemistry, and histology. We performed tau by ELISA. We detected 14-3-3 protein by Western blot. Both assays were optimized for maximum efficiency (accuracy). RESULTS: We found tau and 14-3-3 proteins to be closely correlated, but tau had a significantly better ability to predict disease status than 14-3-3 protein. Also, tau distinguished disease status at least as well as when both assays' results are combined in a variety of ways. Importantly, the area under the receiver operating characteristic curve for tau (0.82) was significantly larger than that for 14-3-3 protein (0.68) (p < 0.001). Diagnostic test statistics are provided for the study subjects with 58.3% prevalence, and for a more typical, nonselected, 7.5% prevalence as received by our center. CONCLUSION: In this study, tau is superior to 14-3-3 protein as a marker in the diagnosis of Creutzfeldt-Jakob disease, and is as efficient singly compared to a variety of combinations with 14-3-3 protein. This is the first study of this magnitude to examine prion disease diagnostic tests in a carefully characterized patient population with detailed statistical evaluation.
OBJECTIVE: To compare the respective efficiency of CSF tau (quantitative) and CSF 14-3-3 protein (qualitative) in the diagnosis of prion disease. METHODS: We made measurements on 420 live subjects, who subsequently underwent a postmortem neuropathology examination, including protein chemistry, immunohistochemistry, and histology. We performed tau by ELISA. We detected 14-3-3 protein by Western blot. Both assays were optimized for maximum efficiency (accuracy). RESULTS: We found tau and 14-3-3 proteins to be closely correlated, but tau had a significantly better ability to predict disease status than 14-3-3 protein. Also, tau distinguished disease status at least as well as when both assays' results are combined in a variety of ways. Importantly, the area under the receiver operating characteristic curve for tau (0.82) was significantly larger than that for 14-3-3 protein (0.68) (p < 0.001). Diagnostic test statistics are provided for the study subjects with 58.3% prevalence, and for a more typical, nonselected, 7.5% prevalence as received by our center. CONCLUSION: In this study, tau is superior to 14-3-3 protein as a marker in the diagnosis of Creutzfeldt-Jakob disease, and is as efficient singly compared to a variety of combinations with 14-3-3 protein. This is the first study of this magnitude to examine prion disease diagnostic tests in a carefully characterized patient population with detailed statistical evaluation.
Authors: K Gmitterová; U Heinemann; M Bodemer; A Krasnianski; B Meissner; H A Kretzschmar; I Zerr Journal: Neurobiol Aging Date: 2008-03-06 Impact factor: 4.673
Authors: S Kropp; I Zerr; W J Schulz-Schaeffer; C Riedemann; M Bodemer; C Laske; H A Kretzschmar; S Poser Journal: Neurosci Lett Date: 1999-02-12 Impact factor: 3.046
Authors: P Sanchez-Juan; A Green; A Ladogana; N Cuadrado-Corrales; R Sáanchez-Valle; E Mitrováa; K Stoeck; T Sklaviadis; J Kulczycki; K Hess; M Bodemer; D Slivarichová; A Saiz; M Calero; L Ingrosso; R Knight; A C J W Janssens; C M van Duijn; I Zerr Journal: Neurology Date: 2006-08-22 Impact factor: 9.910
Authors: P Beaudry; P Cohen; J P Brandel; N Delasnerie-Lauprêtre; S Richard; J M Launay; J L Laplanche Journal: Dement Geriatr Cogn Disord Date: 1999 Jan-Feb Impact factor: 2.959
Authors: Pascual Sanchez-Juan; Raquel Sánchez-Valle; Alison Green; Anna Ladogana; Natividad Cuadrado-Corrales; Eva Mitrová; Kathrina Stoeck; Theodoros Sklaviadis; Jerzy Kulczycki; Klaus Hess; Anna Krasnianski; Michele Equestre; Danka Slivarichová; Albert Saiz; Miguel Calero; Maurizio Pocchiari; Richard Knight; Cornelia M van Duijn; Inga Zerr Journal: J Neurol Date: 2007-03-25 Impact factor: 4.849
Authors: Michael D Geschwind; Jennifer Martindale; Deborah Miller; Stephen J DeArmond; Jane Uyehara-Lock; David Gaskin; Joel H Kramer; Nicholas M Barbaro; Bruce L Miller Journal: Arch Neurol Date: 2003-06
Authors: M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira Journal: J Neurol Date: 2016-06-29 Impact factor: 4.849
Authors: Aaron Foutz; Brian S Appleby; Clive Hamlin; Xiaoqin Liu; Sheng Yang; Yvonne Cohen; Wei Chen; Janis Blevins; Cameron Fausett; Han Wang; Pierluigi Gambetti; Shulin Zhang; Andrew Hughson; Curtis Tatsuoka; Lawrence B Schonberger; Mark L Cohen; Byron Caughey; Jiri G Safar Journal: Ann Neurol Date: 2017-01 Impact factor: 10.422